Goodwill and Intangible Assets, Net

3 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

The changes in the carrying amount of goodwill for the three months ended March 31, 2017 are as follows:



Balance at December 31, 2016	$	157,175
Foreign currency translation adjustments	650
Balance at March 31, 2017	$	157,825

No goodwill or accumulated impairment losses existed as of March 31, 2017 and December 31, 2016.

Intangible assets consist of the following at March 31, 2017:



	Weighted Average Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Patents, developed technologies and know-how	15.9	$	238,513	$	(33,789	)	$	204,724
Customer relationships	6.5	10,700		(5,156		)	5,544
Trademarks	9.3	6,800		(1,986		)	4,814
In-process research and development		7,992		—			7,992
Total		$	264,005	$	(40,931	)	$	223,074

Intangible assets consist of the following at December 31, 2016:



	Gross Carrying Amount		Accumulated Amortization			Net
Patents, developed technologies and know-how	$	236,401	$	(29,748	)	$	206,653
Customer relationships	10,700		(4,672		)	6,028
Trademarks	6,800		(1,792		)	5,008
Covenant not to compete	370		(339		)	31
In-process research and development	7,895		—			7,895
Total	$	262,166	$	(36,551	)	$	225,615

The balance of in-process research and development as of March 31, 2017 includes certain in-process research and development technology acquired in the Company's acquisition of Oxitec in September 2015, and amortization will begin once certain regulatory approvals have been obtained for the in-process programs.

Amortization expense was $4,618 and $3,515 for the three months ended March 31, 2017 and 2016, respectively.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details